

Washington, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-1019, [tisha.washington@fda.hhs.gov](mailto:tisha.washington@fda.hhs.gov) no later than September 4, 2018.

*Requests for Oral Presentations:*

During online registration you may indicate if you wish to present at the public comment session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by September 5, 2018. All requests to make oral presentations must be received by the close of registration on September 4, 2018. If selected for presentation, any presentation materials must be emailed to Tisha Washington (see **FOR FURTHER INFORMATION CONTACT**) no later than close of business, September 6, 2018. No commercial or promotional material will be permitted to be presented or distributed at the public workshop.

*Streaming Webcast of the Public Workshop:* This public workshop will also be webcast. The webcast link will be available on the following web page 5 days before the workshop at: <https://www.fda.gov/Drugs/NewsEvents/ucm611203.htm>.

If you have never attended a Connect Pro event before, test your connection at [https://collaboration.fda.gov/common/help/en/support/meeting\\_test.htm](https://collaboration.fda.gov/common/help/en/support/meeting_test.htm). To get a quick overview of the Connect Pro program, visit [https://www.adobe.com/go/connectpro\\_overview](https://www.adobe.com/go/connectpro_overview). FDA has verified the website addresses in this document, as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

*Transcripts:* Please be advised that as soon as a transcript of the public workshop is available, it will be accessible at <https://www.regulations.gov>. It may be viewed at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. A link to the transcript will also be available on the internet at <https://www.fda.gov/Drugs/NewsEvents/ucm611203.htm>.

Dated: August 6, 2018.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2018-17130 Filed 8-9-18; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### HHS Approval of Entities That Certify Medical Review Officers

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice publishes a list of the Department of Health and Human Services (HHS) approved Medical Review Officers certification entities. The HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines), applicable on October 1, 2017, addresses the role and qualifications of Medical Review Officers (MROs) and HHS approval of entities that certify MROs.

**FOR FURTHER INFORMATION CONTACT:**

Sean J. Belouin, Pharm.D., CAPT, United States Public Health Service, Senior Pharmacology and Regulatory Policy Advisor, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland 20857; Telephone: (240) 276-2716; Email: [sean.belouin@samhsa.hhs.gov](mailto:sean.belouin@samhsa.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Subpart M—Medical Review Officer (MRO), Section 13.2 of the Mandatory Guidelines, “How are nationally recognized entities or subspecialty boards that certify MROs approved?” states as follows: “All nationally recognized entities or subspecialty boards which seek approval by the Secretary to certify physicians as MROs for federal workplace drug testing programs must submit their qualifications, a sample examination, and other necessary supporting examination materials (e.g., answers, previous examination statistics or other background examination information, if requested) (OMB Control No.: 0930-0158). Approval will be based on an objective review of qualifications that include a copy of the MRO applicant application form, documentation that the continuing education courses are accredited by a professional organization, and the delivery method and content of the examination. Each approved MRO certification entity must

resubmit their qualifications for approval every two years. The Secretary shall publish at least every two years a notice in the **Federal Register** listing those entities and subspecialty boards that have been approved. This notice is also available on the internet at <http://www.samhsa.gov/workplace/drug-testing>.”

HHS has completed its review of entities that certify MROs, in accordance with requests submitted by such entities to HHS.

The HHS Secretary approves the following MRO certifying entities that offer MRO certification through examination:

American Association of Medical Review Officers (AAMRO), P.O. Box 12873, Research Triangle Park, NC 27709, Phone: (919) 489-5407, Fax: (919) 490-1010, Email: [bbrandon@aamro.com](mailto:bbrandon@aamro.com), website: <http://www.aamro.com/>.

Medical Review Officer Certification Council (MROCC), 3231 S. Halsted St, #167, Chicago, IL 60608, Phone: (847) 631-0599, Fax: (847) 483-1282, Email: [mrocc@mrocc.org](mailto:mrocc@mrocc.org), website: <http://www.mrocc.org/>.

**DATES:** HHS approval is effective July 31, 2018.

**Alex M. Azar II,**  
*Secretary.*

[FR Doc. 2018-17184 Filed 8-9-18; 8:45 am]

**BILLING CODE 4162-20-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Alcohol Abuse and Alcoholism; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Alcohol Abuse and Alcoholism.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Alcohol Abuse and Alcoholism.

*Closed:* September 13, 2018.

*Time:* 9:00 a.m. to 9:45 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700-B Rockledge Drive, Conference Rooms A & B, Bethesda, MD 20817.

*Open:* September 13, 2018.

*Time:* 9:45 a.m. to 3:00 p.m.

*Agenda:* Presentations and other business of the Council.

*Place:* National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700-B Rockledge Drive, Conference Rooms A & B, Bethesda, MD 20817.

*Contact Person:* Abraham P. Bautista, Ph.D., Executive Secretary, National Advisory Council, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 6700-B Rockledge Drive, Suite 1458, MSC 6902, Bethesda, MD 20892, 301-443-9737 [bautista@mail.nih.gov](mailto:bautista@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <https://www.niaaa.nih.gov/news-events/meetings-events-exhibits>, where an agenda and any additional information for the meetings will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: August 6, 2018.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2018-17107 Filed 8-9-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; ADC P30 Review.

*Date:* September 17-18, 2018.

*Time:* 2:00 p.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Garden Inn, 7301 Waverly St., Bethesda, MD 20814.

*Contact Person:* Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Room 2C218, Bethesda, MD 20892, 301-496-9374, [grimaldim2@mail.nih.gov](mailto:grimaldim2@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: August 6, 2018.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2018-17103 Filed 8-9-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Chronic Pain: The Science of Complementary and Integrative Health Approaches

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** This symposium on September 11, 2018, sponsored by the National Center for Complementary and Integrative Health, will bring leading researchers to discuss the science and potential uses of complementary and integrative health approaches in treating chronic pain.

**DATES:** The meeting will be held on September 11, 2018, from 8:30 a.m. to 5:30 p.m.

**ADDRESSES:** The meeting will be held at the Boston Convention and Exhibition Center, 415 Summer Street, Boston, MA 02210.

**FOR FURTHER INFORMATION CONTACT:** For information concerning this meeting, see the NCCIH website, <https://nccih.nih.gov/chronic-pain-symposium-2018?nav=govd>, the 17th World Congress on Pain website, <https://www.iaspworldcongressonpain.org/program/current-satellite-symposia/>

[#toggle-id-3](#), or contact Dr. Wen Chen, Acting Branch Chief and Program Director, Basic and Mechanistic Research, Division of Extramural Research, National Center for Complementary and Integrative Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, telephone: 301-451-3989; email: [when.chen2@nih.gov](mailto:when.chen2@nih.gov).

**SUPPLEMENTARY INFORMATION:** This symposium, sponsored by the National Center for Complementary and Integrative Health, will bring leading researchers from multiple disciplines to discuss the science and potential uses of complementary and integrative health approaches in treating chronic pain. The symposium will highlight current concerns regarding the opioid epidemic and the potential roles of complementary and integrative health approaches in addressing this crisis. The objectives of the symposia are to: Present the past, present, and future of natural products research and pain management, focusing on our current understanding of the ascending and descending neural mechanisms by which different natural products may contribute to analgesia; ascertain the mechanisms by which a variety of mind and body approaches may modulate pain; and discuss translational potential for complementary and integrative approaches for individual-based chronic pain management.

Interested individuals can register for the symposia at: <https://www.iaspworldcongressonpain.org/registration/>. Once you have created a free IASP account, you can choose to register for a Satellite Symposium only. Choose the Satellite Symposium "Chronic Pain: The Science of Complementary and Integrative Health Approaches." The registration fee is \$20 for the 1-day symposium.

Dated: August 6, 2018.

**David Shurtleff,**

*Acting Director, National Center for Complementary and Integrative Health, National Institutes of Health.*

[FR Doc. 2018-17118 Filed 8-9-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.